Skip to main content

Nuo Therapeutics, Inc.

corporate_fare Company Profile

Nuo Therapeutics, Inc.

AURX·OTC·Industrial Applications And Services·CIK 0001091596

Nuo Therapeutics, Inc. is a commercial-stage medical device company that develops and markets products for chronic wound care, primarily within the U.S. The company focuses on innovative cell-based technologies that utilize the human body's regenerative capacity to promote natural healing. These autologous biological therapies, derived from the patient's own body, are part of a clinical strategy aimed at improving long-term recovery in complex chronic conditions with significant unmet medical needs. The company was originally organized in 1998 as Informatix Holdings, Inc., later changing its name to Autologous Wound Therapy, Inc. in 1999, and then to Cytomedix, Inc. in 2000. In September 2007, Cytomedix received Section 510(k) clearance from the U. S. Food and Drug Administration (FDA) for the AutoloGel™ System, now known as the Aurix System, for processing peripheral blood into an autologous platelet rich plasma (PRP) for wound management. In 2010, Cytomedix acquired the Angel Whole Blood Separation System from Sorin Group USA, Inc. In 2012, Cytomedix acquired Aldagen, Inc., a privately held developmental cell-therapy company, which remains a non-operational, wholly owned subsidiary. In 2014, Cytomedix changed its name to Nuo Therapeutics, Inc. The company ceased standard operational activities in May 2019, awaiting developments regarding Medicare coverage for Aurix. In April 2021, the Centers for Medicare & Medicaid Services (CMS) issued a favorable National Coverage Determination (NCD) for autologous PRP products, and the company restarted business activities in October 2021. The company's principal offices are located in Houston, Texas.

Nuo Therapeutics, Inc. (OTC:AURX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 11 items for AURX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AURX spans 8-K, 10-Q, SCHEDULE 13D/A.

Recent high-impact activity:

  • Nuo Posts 80% Q3 Revenue Growth, Wins 7% Medicare Reimbursement Increase for 2027
  • Nuo Q3 Revenue Jumps 81% to $1.87M, But Going Concern Doubt Persists on $81K Cash
  • Nuo Therapeutics Q2 Revenue Jumps 150% to $1.77M, Loss Narrows to $167K
  • Nuo Therapeutics Q2 Revenue Jumps 150% as Losses Narrow; Loan Amended
  • Supply Chain Disruption and Going Concern Doubt Flagged by Nuo Therapeutics

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.31M
Net Income
-$2.51M
Op. Cash Flow
-$864.97K
Free Cash Flow
-$1.14M
Gross Profit
$2.22M
Operating Income
-$2.52M
Cash & Equivalents
$548.95K
Debt / Equity
0.00×
Net Margin
-75.8%
Shares Outstanding
48.18M sh
Source: 10-K · filed 2026-03-30 · accession 0001437749-26-010360

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 4,326 shares in AURX as of the October 30, 2026 settlement, a 4872.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 99.1% of AURX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,326 shares as of October 30, 2026
Change vs prior period▲ 4872.4%
Days to cover1.00 at avg daily volume of 20,537
Daily short volume (FINRA facilities)99.1% of 11,100 shares on November 20, 2026

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.9135 -14.83% today
52-week range · as of 2026-11-17 $0.77 – $3.23
Market cap
$44.38M
Volume
11.1K (1.5× avg)
3-mo avg 7.2K
Live data · 2026-11-21 03:25 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed AURX - Latest Insights

AURX
Nov 17, 2026, 8:57 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.09
Real-time Price: $0.9135 info
Change: -$0.1765 (-16%) info
Market Cap: $44.383M info
AURX
Nov 13, 2026, 5:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $0.9135 info
Change: -$0.1765 (-16%) info
Market Cap: $44.383M info
AURX
Aug 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.9135 info
Change: +$0.1435 (+19%) info
Market Cap: $44.383M info
AURX
Aug 17, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.9135 info
Change: +$0.1435 (+19%) info
Market Cap: $44.383M info
AURX
Aug 14, 2026, 5:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.770
Real-time Price: $0.9135 info
Change: +$0.1435 (+19%) info
Market Cap: $44.383M info
AURX
Jun 03, 2026, 11:04 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $0.9135 info
Change: -$0.1465 (-14%) info
Market Cap: $44.383M info
AURX
Jun 03, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.9135 info
Change: -$0.1565 (-15%) info
Market Cap: $44.383M info
AURX
Jun 02, 2026, 5:41 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.07
Real-time Price: $0.9135 info
Change: -$0.1565 (-15%) info
Market Cap: $44.383M info
AURX
May 14, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $0.9135 info
Change: -$0.4365 (-32%) info
Market Cap: $44.383M info
AURX
May 14, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $0.9135 info
Change: -$0.4365 (-32%) info
Market Cap: $44.383M info
AURX
Mar 30, 2026, 5:45 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.44
Real-time Price: $0.9135 info
Change: -$0.5265 (-37%) info
Market Cap: $44.383M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets